title: Risk of bowel perforation in patients receiving interleukin-2 after therapy with anti-CTLA 4 monoclonal antibody.
authors.forename: Franz O
authors.initials: FO
authors.lastname: Smith
authors.forename: Stephanie L
authors.initials: SL
authors.lastname: Goff
authors.forename: Jacob A
authors.initials: JA
authors.lastname: Klapper
authors.forename: Catherine
authors.initials: C
authors.lastname: Levy
authors.forename: Tamika
authors.initials: T
authors.lastname: Allen
authors.forename: Sharon A
authors.initials: SA
authors.lastname: Mavroukakis
authors.forename: Steven A
authors.initials: SA
authors.lastname: Rosenberg
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000628:therapy; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology; D007416:Intestinal Perforation / Q000139:chemically induced*; D000074324:Ipilimumab; D007680:Kidney Neoplasms / Q000628:therapy; D008545:Melanoma / Q000628:therapy
chemical_list: D000911:Antibodies, Monoclonal; D007376:Interleukin-2; D000074324:Ipilimumab